JP2020523317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523317A5 JP2020523317A5 JP2019567635A JP2019567635A JP2020523317A5 JP 2020523317 A5 JP2020523317 A5 JP 2020523317A5 JP 2019567635 A JP2019567635 A JP 2019567635A JP 2019567635 A JP2019567635 A JP 2019567635A JP 2020523317 A5 JP2020523317 A5 JP 2020523317A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- compound
- pharmaceutical composition
- liquid pharmaceutical
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 229940125904 compound 1 Drugs 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 19
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- 229940049920 malate Drugs 0.000 claims description 4
- 208000037843 metastatic solid tumor Diseases 0.000 claims description 4
- 230000000405 serological effect Effects 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 239000007916 tablet composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- ONIQOQHATWINJY-UHFFFAOYSA-N COc(c(OC)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O Chemical compound COc(c(OC)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- 0 COc(c(OC=C*)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O Chemical compound COc(c(OC=C*)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517736P | 2017-06-09 | 2017-06-09 | |
| US62/517,736 | 2017-06-09 | ||
| US201762520768P | 2017-06-16 | 2017-06-16 | |
| US62/520,768 | 2017-06-16 | ||
| PCT/US2018/036703 WO2018227119A1 (en) | 2017-06-09 | 2018-06-08 | Liquid dosage forms to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523317A JP2020523317A (ja) | 2020-08-06 |
| JP2020523317A5 true JP2020523317A5 (https=) | 2021-07-26 |
| JP7249962B2 JP7249962B2 (ja) | 2023-03-31 |
Family
ID=62779087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567635A Active JP7249962B2 (ja) | 2017-06-09 | 2018-06-08 | がんを治療するための液体剤形 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11504362B2 (https=) |
| EP (1) | EP3634413A1 (https=) |
| JP (1) | JP7249962B2 (https=) |
| KR (1) | KR102647794B1 (https=) |
| CN (1) | CN110678180A (https=) |
| AU (1) | AU2018279834B2 (https=) |
| CA (1) | CA3065560A1 (https=) |
| MX (1) | MX2019014298A (https=) |
| UA (1) | UA126402C2 (https=) |
| WO (1) | WO2018227119A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013020362A2 (pt) * | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
| AU2018279834B2 (en) | 2017-06-09 | 2024-05-23 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
| CN117402114A (zh) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
| WO2024163400A1 (en) | 2023-01-31 | 2024-08-08 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| US7989490B2 (en) * | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| PE20131137A1 (es) * | 2010-10-29 | 2013-10-03 | Troikaa Pharmaceuticals Ltd | Composiciones nasales de vitamina b12 |
| MX2013012695A (es) | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
| EP2758057B1 (en) * | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| ITRM20120331A1 (it) | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
| JP6464084B2 (ja) | 2012-07-27 | 2019-02-06 | イズミ テクノロジー，エルエルシー | 排出阻害剤およびこれを用いる治療法 |
| BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
| UA121655C2 (uk) | 2014-04-25 | 2020-07-10 | Екселіксіс, Інк. | Спосіб лікування аденокарциноми легень |
| EP3174854B1 (en) * | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| AU2018279834B2 (en) | 2017-06-09 | 2024-05-23 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
-
2018
- 2018-06-08 AU AU2018279834A patent/AU2018279834B2/en active Active
- 2018-06-08 WO PCT/US2018/036703 patent/WO2018227119A1/en not_active Ceased
- 2018-06-08 EP EP18735102.8A patent/EP3634413A1/en not_active Withdrawn
- 2018-06-08 MX MX2019014298A patent/MX2019014298A/es unknown
- 2018-06-08 CN CN201880035207.9A patent/CN110678180A/zh active Pending
- 2018-06-08 US US16/620,379 patent/US11504362B2/en active Active
- 2018-06-08 KR KR1020207000409A patent/KR102647794B1/ko active Active
- 2018-06-08 UA UAA201912200A patent/UA126402C2/uk unknown
- 2018-06-08 CA CA3065560A patent/CA3065560A1/en active Pending
- 2018-06-08 JP JP2019567635A patent/JP7249962B2/ja active Active
-
2022
- 2022-10-28 US US17/975,765 patent/US12016854B2/en active Active
-
2024
- 2024-05-10 US US18/661,030 patent/US20240307367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523317A5 (https=) | ||
| JP2022009090A5 (https=) | ||
| JP2023516291A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| RU2640485C2 (ru) | Комбинированное лечение рака | |
| JP2016515628A5 (https=) | ||
| JP2019532051A5 (https=) | ||
| JP2013501731A5 (https=) | ||
| JP2004531549A5 (https=) | ||
| JP2019517587A5 (https=) | ||
| JP2010532373A5 (https=) | ||
| JP2022540421A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2019516684A5 (https=) | ||
| JP2019530713A5 (https=) | ||
| JP2021504384A5 (https=) | ||
| JP2018531605A5 (https=) | ||
| JP2022508513A5 (https=) | ||
| JP2018530578A5 (https=) | ||
| JP2019508476A5 (https=) | ||
| CN1283248C (zh) | 包含埃坡霉素的组合及其药学应用 | |
| BR112020009452A2 (pt) | Derivado de cumarina para terapia ou profilaxia de um distúrbio proliferativo celular | |
| JP2019531286A5 (https=) | ||
| KR20040106422A (ko) | 간암 및 다른 암 질병 치료용 에포틸론 유도체 | |
| JP2023011549A5 (https=) |